Senseonics targets Gemini for 2027 and Freedom for 2028, expects 2026 cash burn of about $120 million, and anticipates a margin profile north of 60% next year, with Freedom margins north of 70%.
SENS · Senseonics Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $8.91
- Open
- $9.80
- Day range
- $8.76–10.15
- 52-week closing range
- $4.86–10.90
- Average volume, 30 days
- 959K
- Short interest
- 4.7M · 8.7% of shares · 7.8 days
- Short volume, last session
- 37%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Senseonics reported third-quarter 2026 revenue of $19.6 million, up approximately 140%, and raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million.
Senseonics reported revenue of $19.6 million for the three months ended September 30, 2026, up from $8.1 million, while gross margin improved to 61.7% from 42.8%.
Senseonics Holdings, Inc. generated third quarter revenue of $19.6 million, up approximately 140% year-over-year, and raised full-year 2026 revenue guidance to $68 million to $70 million. Gross margin was approximately 62%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. Third-quarter revenue grew approximately 140%, with full-year revenue and gross-margin guidance raised, while EON Care expanded and the Beta Bionics and Freedom initiatives advanced. The company remained loss-making as R&D and SG&A increased, operating expenses are expected slightly above the prior guidance range, cash use is expected at the high end of the prior range, and Europe is expected to represent approximately 15% of full-year revenue, down from 20%.
- + Third-quarter revenue reached $19.6 million, up approximately 140% year over year.
- + Full-year 2026 revenue guidance was raised to $68 million-$70 million from $62 million-$66 million.
- + Third-quarter gross margin was approximately 62%, and full-year gross-margin guidance was raised to more than 60%.
- + The EON Care network exceeded its 100-inserter year-end goal and is expected to reach approximately 120 inserters by year-end.
- + Senseonics announced a Beta Bionics partnership to integrate Eversense 365 with the iLet Bionic Pancreas, with commercial launch planned for the fourth quarter of 2026.
- + Senseonics initiated the first-in-human study of Freedom, an investigational CGM without an on-body component.
- − Net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43 per share.
- − Research and development expense increased to $11.7 million from $7.8 million.
- − Selling, general and administrative expense increased to $32.3 million from $15.3 million.
- − Full-year operating expenses are expected to come in slightly above the previous guidance range of $150 million-$160 million.
- − Four-year cash utilization is expected at the high end of the prior range, or approximately $120 million.
- − Europe is expected to represent approximately 15% of full-year revenue, down from the previously discussed 20%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, restricted cash and short-term investments | $126.6M | As of September 30, 2026 | — |
| EON Care network inserters | 100 | third quarter | — |
| Principal borrowings outstanding under the Hercules Capital facility | $55M | As of September 30, 2026 | — |
| Share of third quarter Eversense insertion procedures performed by EON Care inserters | 40% | third quarter | — |
| Capital raised during Q2 | $100M | Q2 2026 | — |
| Eon Care nurses | 90 | Q2 2026 | — |
| Equity proceeds raised in Q2 | $90M | Q2 2026 | — |
| Expanded Hercules Capital facility capacity | $140M | Q2 2026 | — |
| Share of Eversense insertion procedures via Eon Care | 40% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SENS
this stock
Senseonics Holdings, Inc.
|
$487.82M | +61.3% | +19.8% | — | 8.7% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 21
Senseonics targets Gemini for 2027 and Freedom for 2028, expects 2026 cash burn of about $120 million, and anticipates a margin profile north of 60% next year, with Freedom margins north of 70%.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SENS | -11.3% | +20.3% | +30.2% | -6.4% | +61.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -5.9% | +26.6% | +35.8% | -1.1% | +56.3% |